天原集團(002386.SZ):新興產業公司增資天億新材料的增資款已到賬
格隆匯9月2日丨天原集團(002386.SZ)公佈,公司第八屆董事會第四次會議審議通過了《關於子公司引進戰略投資者暨關聯交易的議案》。同意天原集團下屬全資子公司宜賓天億新材料科技有限公司(簡稱:天億新材料)引入戰略投資者,其中宜賓市新興產業投資集團有限公司(簡稱新興產業公司)擬通過非公開方式對天億新材料現金增資2億元。
新興產業公司以非公開方式增資天億新材料的增資款已到賬,並於2020年9月1日完成工商註冊登記和取得宜賓市市場監督管理局頒發的《營業執照》。至此天億新材料註冊資本由2億元變更為311,731,800元,其中天原集團出資佔比為64.16%,新興產業公司出資佔比為35.84%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.